Inherited susceptibility to prostate cancer has been linked to a number of chromosomal regions, however no genes have been unequivocally shown to underlie reported linkages. The putative gene localised to chromosome 1q42 -q43, has been designated PCaP. We have recently shown that germline mutations in the fumarate hydratase (FH) gene located on 1q43 cause smooth muscle tumours and renal cell carcinoma. It is conceivable that germline FH mutations might confer an increased risk of prostate cancer and underlie linkage of prostate cancer to PCaP. To examine this proposition we have analysed the entire coding region of FH in 160 prostate cancer cases in 77 multiple case families. No pathogenic mutations in FH were identified in any of the cases. This data makes it highly unlikely that mutations in FH confer susceptibility to prostate cancer.
Introduction
Prostate cancer is the single most common non-cutaneous malignancy and is the second leading cause of cancer mortality in the United Kingdom (MIM 176807). An estimated 17 000 cases were diagnosed in 1998, with an estimated 8500 deaths due to prostate cancer. 1 In addition to age and race, family history is a strong risk factor, indicating that inherited genetic factors play an important role in the aetiology of the disease. 2 Approximately 10% of cases occur in families with several affected family members 3 and epidemiological studies have shown that the risk of the disease is increased 2 to 3-fold in men with an affected first-degree relative. 4 Hereditary prostate cancer is an etiologically heterogeneous disease. The existence of rare, highly penetrant dominant susceptibility genes for prostate cancer has been supported by segregation analyses of prostate cancer families, 5 -7 and genome-wide linkage searches and karyotype analysis have indicated several regions that may be implicated in inherited prostate cancer: HPC1 (1q24 -q25); 8 PCaP (1q42 -q43); 9 HPCX (Xq27 -q28); 10 CAPB (1p36); 11 HPC20 (20q13); 12 HPC2/ECAC2 (17p11); 13 and 10q25. 14 Confirmation studies at these loci have produced discordant results however, which may reflect in part the fact that individual research groups are analysing unique sets of families. In keeping with this notion are recent results suggesting that PCaP is the most frequent locus predisposing to hereditary prostate cancer cases from European families. 15 We have recently shown that germline mutations in the fumarate hydratase (FH) gene located on 1q43 predispose to smooth muscle tumours and renal cell carcinoma. 16 Although many individuals harbouring germline FH mutations manifest cutaneous leiomyomas, this phenotype can be minimal or absent in carriers. Hence it is conceivable that germline FH mutations might confer an increased risk of prostate cancer and underlie linkage of prostate cancer to PCaP. To examine this proposition we have analysed the coding region of FH in 160 prostate cancer cases in 77 multiple case families ascertained in the United Kingdom.
Families and methods Families
Seventy-seven prostate cancer families ascertained by the Cancer Research UK (formerly Cancer Research Campaign)/British Prostate Group (CRC/BPG) UK familial prostate cancer study consortium were studied. They comprised 35 two-case families, 19 three-case families, 18 four-case families, 3 five-case families and 1 six-case family and 1 family with eight cases of prostate cancer. The average age at diagnosis of prostate cancer was 65.6 y. The total number of affected men available for screening was 160 (average number per family 2.1). All samples and clinical information were obtained with informed consent and the studies were approved by local ethics committees in accordance with the tenets of the Declaration of Helsinki. DNA was salt extracted from EDTA venous blood samples using a standard sucrose lysis protocol.
Detection of FH mutations
The amplification of the exons and intron -exon junctions, including splice sites of FH was carried out by PCR of genomic DNA using the primers detailed in Table 1 . PCR products were generated using a 32 Pg-dATP end labelled primer and were analysed for mutations by conformational sensitive gel electrophoresis (CSGE) as described previously. 17 Any fragments showing migration shifts were re-amplified and sequenced directly using the ABI Prism dRhodamine Terminator Cycle Sequencing Ready Reaction Kit and an ABI377 Genetic Analyser. Nucleotide changes identified were coded according to the published sequence of FH (Genbank accession number XM_050665).
Results and discussion
Prompted by our recent finding that mutations in FH confer susceptibility to cancer 16 we have examined a series of 77 families containing 160 individuals affected with prostate cancer for germline mutations. The criteria for inclusion in this study was that at least one affected individual from each family had been diagnosed with early-onset prostate cancer, or at least three affected cases of any age in a single family, this significantly enriches cases for genetic susceptibility.
The FH gene consists of 10 exons, the first of which encodes a signal peptide facilitating mitochondria transport of the expressed protein. Here we have screened the full coding sequence and splice junctions of FH in all of the prostate cancer cases from the 77 families.
Two nucleotide sequence changes were identified. The first was a G -A synonymous substitution at position 3 of codon 309 encoding proline, identified in six affected individuals. The second sequence change identified in four affected individuals was a G -A substitution 46 bp into intron 6. Neither of these changes segregated with disease in the families. No clearly pathogenic mutations -truncating or splice site mutations -were detected in any of the patients studied.
We cannot exclude the possibility that a minority of mutations may have been missed, but under test conditions we have found that CSGE can detect all small insertions and deletions and 90% of single base substitutions, and the technique detected a number of single base substitution polymorphisms within the gene.
A large number of loci have recently been proposed as having significance in prostate cancer. However, to date no genes underlying these regions have been unequivocally shown to cause disease. Given the inability to replicate linkage findings, gene identification through refinement of linkage is likely to be problematic. In view of this, screening of candidates within regions of linkage represents an attractive strategy. Here we have shown that whilst FH represented an attractive candidate our data strongly indicates that constitutional mutations in this gene are unlikely to confer an increased risk of prostate cancer. 1  TGTGAGGCTGTTGATTGGAT  GGAGGGCTGAAGGTCACTG  298  2  GATGCGATTACTTTTGAT  CATGAATACAGCCTACTT  256  3  AACTTCCATGCTTAAGTA  ATCGTCATCCAGACTATG  230  4  GTCAACTGTATTCAACT  TTCAATTTATAACCAAAA  299  5  TTTTATATTTCTTTTGAA  TTAAGCTAGTCAGATTTC  297  6  TAACTTGTAAGCTATTAG  ACATGTTTGATGGAAAAA  355  7  TGTTTCACTTGCTAATGG  GGTCCATAGCTAAGAATG  348  8  GCTTTATTGTATATCTTA  TAGAAGTCTTTATGAAAT  311  9  CATGTTGCCTTAGTAATGTCTCTCTC  TGCTGTTCTCAAACACTGATCC  261  10 ATGTCACCTTTTGCTTTA TCCGTTTTTAAGAAATGG 287
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